PT - JOURNAL ARTICLE AU - Lumley, Sheila F. AU - Richens, Nicholas AU - Lees, Emily AU - Cregan, Jack AU - Kalimeris, Elizabeth AU - Oakley, Sarah AU - Morgan, Marcus AU - Segal, Shelley AU - Dawson, Moya AU - Walker, A. Sarah AU - Eyre, David W. AU - Crook, Derrick W. AU - Beer, Sally AU - Novak, Alex AU - Stoesser, Nicole E. AU - Matthews, Philippa C. TI - Changes in paediatric respiratory infections at a UK teaching hospital 2016-2021; impact of the SARS-CoV-2 pandemic AID - 10.1101/2021.10.13.21264956 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.13.21264956 4099 - http://medrxiv.org/content/early/2021/10/16/2021.10.13.21264956.short 4100 - http://medrxiv.org/content/early/2021/10/16/2021.10.13.21264956.full AB - Objective To describe the impact of the SARS-CoV-2 pandemic on the incidence of paediatric viral respiratory tract infection in Oxfordshire, UK.Methods Data on paediatric Emergency Department (ED) attendances (0-15 years inclusive), respiratory virus testing, vital signs and mortality at Oxford University Hospitals were summarised using descriptive statistics.Results Between 1-March-2016 and 30-July-2021, 155,056 ED attendances occurred and 7,195 respiratory virus PCRs were performed. Detection of all pathogens was suppressed during the first national lockdown. Rhinovirus and adenovirus rates increased when schools reopened September-December 2020, then fell, before rising in March-May 2021. The usual winter RSV peak did not occur in 2020/21, with an inter-seasonal rise (32/1,000 attendances in 0-3yr olds) in July 2021. Influenza remained suppressed throughout. A higher Paediatric Early Warning Score (PEWS) was seen for attendees with adenovirus during the pandemic compared to pre-pandemic (p=0.04, Mann-Witney U test), no other differences in PEWS were seen.Conclusions SARS-CoV-2 caused major changes in the incidence of paediatric respiratory viral infection in Oxfordshire, with implications for clinical service demand, testing strategies, timing of palivizumab RSV prophylaxis, and highlighting the need to understand which public health interventions are most effective for preventing respiratory virus infections.Competing Interest StatementDWE declares lecture fees from Gilead, outside the submitted work. No other author has a conflict of interest to declare.Funding StatementSFL is a Wellcome Trust Clinical Research Fellow. NES is an Oxford Martin Fellow and an NIHR Oxford BRC Senior Fellow. PCM holds a Wellcome Intermediate Fellowship (110110/Z/15/Z) and is an NIHR Oxford BRC Senior Fellow. DWE is a Robertson Foundation Fellow and an NIHR Oxford BRC Senior Fellow. ASW is an NIHR Senior Investigator. ASW and NS are supported by the NIHR Research Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance at the University of Oxford in partnership with Public Health England (PHE) (NIHR200915). ASW is supported by the NIHR Oxford Biomedical Research Centre.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Deidentified data were obtained from the Infections in Oxfordshire Research Database which has approvals from the National Research Ethics Service Committee South Central Oxford C Research Ethics Committee (19/SC/0403), the Health Research Authority and the national Confidentiality Advisory Group (19/CAG/0144). All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe epidemiological datasets analysed are not publicly available as they contain personal data but are available from the Infections in Oxfordshire Research Database (https://oxfordbrc.nihr.ac.uk/research-themes-overview/antimicrobial-resistance-and-modernising-microbiology/infections-in-oxfordshire-research-database-iord/), subject to an application and research proposal meeting the ethical and governance requirements of the Database.